Researchers from Massachusetts and West Virginia have developed an innovative wireless ingestible device, known as the Vitals Monitoring Pill (VM Pill). This device is potentially capable of transforming how vital signs are monitored and medical conditions diagnosed. The VM Pill is a capsule-sized device, designed to collect and report vital signs, such as respiratory and heart rates, accurately. This advancement is a collaborative effort involving Brigham and Women’s Hospital, Massachusetts Institute of Technology (MIT), Celero Systems, and West Virginia University. The device is equipped with integrated circuits and electronic sensors, including an accelerometer, to measure the small ballistic movements in the gastrointestinal tract caused by heartbeats and breathing. The VM Pill was first evaluated in a preclinical animal model study, where it successfully detected signs of opioid-induced respiratory depression. Following this, a human trial was conducted among patients undergoing a sleep study at West Virginia University (WVU) Medicine. This trial included ten patients and resulted in 57 hours of patient data collection. About 30% of these patients were diagnosed with central or obstructive sleep apnea (OSA) and were using airway pressure devices during the study. The trial demonstrated the VM Pill’s capability to gather respiratory and heart rate data comparable to traditional monitoring devices, capturing respiratory rhythms within the range of 9 to 25 breaths per minute and cardiac signals within 40 to 95 beats per minute. Notably, the VM Pill effectively identified moments when subjects stopped breathing, either due to sleep apnea or intentionally holding their breath, without interference from external sleep apnea monitoring devices.
New Pill To Diagnose Medical Conditions Upon Ingestion
Get the free newsletter
Discover everything you need to become HIPAA compliant